The therapeutic potential for targeting LYN and HS1 in CLL has been assessed in TCL1-tg transplantable mouse model.79In vitro treatment with the tyrosine kinase inhibitor, dasatinib, prevents HS1 and ERK phosphorylation, induces apoptosis and blocks CXCL12 chemotaxis and the interaction with stromal cells. Here, HCLS1 is linked to B-cell chronic lymphocytic leukemia.